Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Thrombosis 1Neoplasms 1Metabolic Diseases 1Malignant Female Reproductive System Neoplasm 1Hematologic Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Catheter-Related Infections 1Bacteremia 1Anemia, Aplastic 1

Interventions

Olanzapine 4Cyclophosphamide 4Voriconazole 3Tranexamic Acid 3Standard of Care 3nilotinib 2letermovir 2fludarabine phosphate 2Zoledronic Acid 2Whole-Body Irradiation 2Practice Guidelines as Topic 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Methods 2Imatinib Mesylate 2Educational Status 2Early Intervention, Educational 2Doxorubicin 2Cyclosporins 2Cyclosporine 2venetoclax 1trihexyltetradecylphosphonium chloride 1thymoglobulin 1shengxuening 1posaconazole 1pembrolizumab 1olaparib 1maribavir 1lenvatinib 1ferrous succinate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Hematologic Neoplasms × Heparin × Clear all
NCT01820962 2013-03-29

Concentrated Citrate Locking to Reduce the Incidence of CVC-related Complications in Hematological Patients

Maastricht University Medical Center

Phase 3 Terminated
212 enrolled
Other hematologic neoplasm

Thrombosis, Bacteremia, Hematologic Neoplasms, Catheter-Related Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡